Molecular biomarkers in non-small cell lung cancer (NSCLC), primarily involving pathogenic alterations in key oncogenes, play a critical role in personalizing cancer treatments. Initially important only for advanced stages, they are now essential in early-stage treatment decisions. In Slovenia, testing for common molecular alterations and PD-L1 expression has been gradually implemented into a routine practice since 2010 for all newly diagnosed non-squamous NSCLC patients, regardless of disease stage. This study aims to report the testing rates and observed frequencies of these molecular alterations.
Published at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2024.
Katja Mohorčič1, Roman Luštrik3, Žan Kuralt3, Mark Uhlik4, Izidor Kern2, Luka Ausec4
1 Medical Oncology Unit, University Clinic Golnik, Slovenia
2 Pathology Department, University Clinic Golnik, Slovenia
3 Genialis, d.o.o., Ljubljana, Slovenia
4 Genialis, Inc., Boston, MA, USA